Company
Viking Therapeutics
NASDAQ:VKTX
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
18 stories
Viking Therapeutics joins weight loss drug bandwagon as trial data impresses
Data from the phase 1 trials of single and multiple doses of VK2735 showed reported weight loss of up to 7.8%
Viking Therapeutics shares pop after rival Gilead's liver drug trial falls short
Viking stands to benefit after Gilead’s drug selonsertib did not meet its primary endpoint in a Phase 3 trial
Viking Therapeutics shares pop on successful Phase 2 test for liver disease
The study achieved both its primary and secondary endpoints
Viking Therapeutics stock rises on positive trial results for treatment of hip fractures
Some 108 patients received doses of the drug over the past 12 weeks
Viking Therapeutics' successful liver treatment trial boosts Madrigal Pharmaceuticals, says Oppenheimer
Both companies manufacture selective thyroid beta-receptor agonists to treat liver disease
Maxim bullish on latest data for Viking Therapeutics' key drug to fight fatty liver disease
The analysts tagged the shares with a Buy rating and upped their price target to US$14
Viking Therapeutics shares rise on rival drug maker's positive liver drug results
The success of Madrigal's clinical trial for its liver drug MGL-3196 bodes well for Viking's own liver drug VK2809
Viking Thereapeutics soars on results of liver disease study
"The preliminary findings suggesting the potential triglyceride-lowering activity of VK2809 in GSD Ia are encouraging," said Professor Dwight Koeberl of Duke University School of Medicine.
Archive
Closing index values
The mid-cap S&P 400 rose nine points to 1,427 and the small-cap Russell 2,000 put on five points at 1,098.
Blue-chip rally runs out of steam but small and mid-caps hold strong
Leading the Nasdaq lower was Viking Therapeutics after it priced its public offering
Viking Therapeutics Inc rockets as H.C. Wainwright starts coverage
Its lead program, VK5211, is an orally available drug candidate under a Phase II clinical trial.
Viking Therapeutics encouraged by early findings of VK5211 study
VK5211 is the company's lead program, and is a treatment for muscle and bone disorders.
TRENDING - Small cap pharma in focus whilst Pfizer dominates blue-chips
While Viagra and Botox were at the attention of blue chip investors, a weight loss drug caught small cap enthusiasm